Taysha Gene Therapies
Taysha Gene Therapies' revenue rose 17.3% to $10 million in fiscal 2025. Its operating margin was −1,130.7%, down from −1,097.5% a year earlier. Free cash flow was −$94 million. The diluted share count rose 27.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Taysha Gene Therapies does
Taysha Gene Therapies is a clinical-stage biotechnology company. It develops gene therapies, built on a harmless virus called AAV, for severe single-gene diseases of the central nervous system. A gene therapy delivers a working copy of a gene into a patient's cells. The company has no approved products.
Its lead program, TSHA-102, is for Rett syndrome, a rare neurodevelopmental disorder caused by mutations in the MECP2 gene. TSHA-102 is meant as a one-time treatment given by injection into the spinal fluid. It is being tested in the REVEAL trials and in a smaller safety study called ASPIRE. The company says it has written agreement with the FDA on the design of its pivotal trial and on the data for a planned application to market the drug. The first patient in the pivotal trial was dosed in the fourth quarter of 2025. The FDA has given the drug several special designations, including orphan drug and Fast Track.
Because it has nothing to sell yet, the company funds itself from outside money. It also relies on a collaboration with UT Southwestern for its early research programs and on contract manufacturers for the AAV9 material.
Its biggest risks, as it describes them
- Losses since it began, with no assurance it will ever be profitable.
- Needing substantial additional funding, or having to cut back its plans.
- No product tested to completion in clinical trials, and no history of selling products.
- Reliance on third-party manufacturers of its AAV9 gene therapy, which face heavy regulation.
- Reliance on UT Southwestern for its early research, and strong competition from other biotechnology and pharmaceutical companies.
Income statement
Taysha Gene Therapies lost money in fiscal 2025: a net loss of $109 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 149 | 88 | 144 | 139 | 320 |
| Debt incl. finance leases | 37 | 39 | 42 | 45 | 50 |
| Net debt (negative means net cash) | −112 | −49 | −102 | −94 | −269 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.4x | — | 0.6x | 0.6x | 0.2x |
| Interest coverage | −121.3x | −42.8x | −14.5x | −896.7x | −1,753.9x |
| Current ratio | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Quick ratio | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
Cash flow
Projections
Project Taysha Gene Therapies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Taysha Gene Therapies reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 4 of 8 |
| Rule of 40 | 19.9% | −1,025.3% | −942.8% |
| Altman Z'' | −7.40 | −10.49 | −0.53 |
| Accruals ratio | −25.8% | −4.8% | −6.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 8 | 4 of 8 | 4 of 8 |
Compare
Put Taysha Gene Therapies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | 2 | 16 | 8 | 10 |
| Revenue growth | — | — | — | 517.5% | −46.1% | 17.3% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 32 | 132 | 91 | 57 | 66 | 86 |
| Operating income | −43 | −173 | −162 | −72 | −92 | −110 |
| Net income | −60 | −174 | −166 | −112 | −89 | −109 |
| Diluted EPS (US$) | −3.40 | −4.64 | −3.78 | −0.96 | −0.36 | −0.34 |
| Diluted shares (millions) | 18 | 38 | 44 | 116 | 250 | 320 |
| Cash flow | ||||||
| Cash from operations | −31 | −117 | −88 | −73 | −81 | −93 |
| Capital expenditure | 0 | 15 | 21 | 4 | 0 | 1 |
| Free cash flow | −31 | −132 | −109 | −77 | −82 | −94 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 18 | 18 | 8 | 13 | 13 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 251 | 149 | 88 | 144 | 139 | 320 |
| Debt incl. finance leases | — | 37 | 39 | 42 | 45 | 50 |
| Total assets | 259 | 214 | 126 | 173 | 160 | 343 |
| Total liabilities | 8 | 119 | 125 | 98 | 89 | 96 |
| Shareholders' equity | 251 | 95 | 1 | 75 | 72 | 247 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | −6,492.7% | −468.8% | −1,097.5% | −1,130.7% |
| Net margin | — | — | −6,635.2% | −722.1% | −1,071.6% | −1,115.3% |
| Free cash flow margin | — | — | −4,356.9% | −497.6% | −979.2% | −960.1% |
| Rule of 40 (growth + FCF margin) | — | — | — | 19.9% | −1,025.3% | −942.8% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −100.7% | −344.7% | −294.0% | −121.9% | −68.5% |
| Return on assets | — | −73.8% | −97.6% | −74.6% | −53.6% | −43.3% |
| Net debt to EBITDA | — | — | — | — | — | — |